Atezolizumab Combo Effective in EGFR-Mutated Non-Small Cell Lung Cancer

The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to results of a final efficacy analysis presented this week at the European Medical Society for Oncology (ESMO) Virtual Congress 2020. "Atezolizumab inhibits programmed death-ligand 1 (PD-L1) to restore anti-cancer immunity; bevacizumab may enhance atezoli...
Continue reading

FDA Alert: Atezolizumab/Paclitaxel Ineffective for Triple-Negative Breast Cancer

The FDA has issued an alert regarding the combination of atezolizumab (Tecentriq®, Genentech) and paclitaxel for the treatment of patients with previously untreated, inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). In addition to being ineffective, atezolizumab/paclitaxel can negatively impact overall survival. While atezolizumab/paclitaxel is not approved for the treatment of breast cancer, atezolizumab in combination with paclitaxel protein-bound particles, also ...
Continue reading

Atezolizumab Triplet Therapy for BRAF V600-Mutant Melanoma: Paolo A. Ascierto, MD

Recently, the FDA approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) and cobimetinib (Cotellic®, Genentech) for the treatment of BRAF V600-mutant advanced melanoma. In this interview with i3 Health, Paolo A. Ascierto, MD, principal investigator of the IMspire150 trial, on which the approval was based, discusses the approval's significance and the most promising research developments in the treatment of BRAF...
Continue reading

Atezolizumab Combo Approved in BRAF V600-Mutant Melanoma

The FDA has approved a new indication for atezolizumab (Tecentriq®, Genentech) in combination with cobimetinib (Cotellic®, Genentech) and vemurafenib (Zelboraf®, Genentech and Daiichi-Sankyo) for the treatment of BRAF V600-mutated advanced melanoma. The approval was granted under a supplemental Biologics License Application (sBLA) with priority review. The approval was based on data from the double-blind, international phase 3 IMspire150 trial (NCT02908672), for which 514 patients with unresecta...
Continue reading

Atezolizumab/Bevacizumab Approved for Unresectable Hepatocellular Carcinoma

The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who have not previously received systemic therapy. The approval was based on IMbrave150 (NCT03434379), a phase 3 trial that enrolled 501 patients with unresectable HCC. Patients were randomized in a 2:1 ratio to receive atezolizumab 1,200 mg administered intravenously followed by be...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.